Elderly patients with early-stage, low-risk (low grade, hormone receptor [HR]-positive, human epidermal growth factor receptor 2 [HER2]-negative) breast cancers are being offered less aggressive adjuvant treatments. This evidence concerns the gene ERBB2 and breast cancer.